BiotechTube

CLS-AX + Aflibercept

Phase 2Completed
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Neovascular Age-related Macular Degeneration

Conditions

Neovascular Age-related Macular Degeneration

Trial Timeline

May 31, 2023 → Aug 20, 2024

NCT ID
NCT05891548

About CLS-AX + Aflibercept

CLS-AX + Aflibercept is a phase 2 stage product being developed by Clearside Biomedical for Neovascular Age-related Macular Degeneration. The current trial status is completed. This product is registered under clinical trial identifier NCT05891548. Target conditions include Neovascular Age-related Macular Degeneration.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT05891548Phase 2Completed

Competing Products

20 competing products in Neovascular Age-related Macular Degeneration

See all competitors
ProductCompanyStageHype Score
CLS-AX + Anti-VEGFClearside BiomedicalPhase 1/2
33
Eylea + ALT-L9AlteogenPhase 1
33
UBX1325 injection 50 μL + EYLEA® (aflibercept) Injection 2 mg (0.05mL)Unity BiotechnologyPhase 2
44
DS-7080a + RanibizumabDaiichi SankyoPhase 1
33
Avacincaptad PegolAstellas PharmaPhase 1
33
Avacincaptad Pegol + Avastin + Lucentis + EyleaAstellas PharmaPhase 2
52
Avacincaptad Pegol + LucentisAstellas PharmaPhase 2
52
KHK4951 + Aflibercept InjectionKyowa KirinPhase 2
52
Surabgene Lomparvovec (ABBV-RGX-314) + Ranibizumab ControlAbbViePhase 3
77
Ranibizumab + Local Steroid + Topical SteroidAbbViePhase 2
52
LucentisNovartisPre-clinical
23
ranibizumabNovartisPhase 3
77
BrolucizumabNovartisPre-clinical
23
ranibizumabNovartisApproved
85
brolucizumab + ranibizumab + afliberceptNovartisPre-clinical
23
BeovuNovartisPre-clinical
23
RanibizumabNovartisPhase 3
77
RanibizumabNovartisApproved
85
Intraviteal Ranibizumab 0.5mgNovartisApproved
85
RanibizumabNovartisApproved
85

Other Products from Clearside Biomedical

4 mg CLS-TA Suprachoriodal InjectionPhase 3
69
suprachoroidal CLS-TA + suprachoroidal sham + Lucentis or AvastinPhase 3
69
4mg CLS-TA Suprachoriodal Injection + Sham ProcedurePhase 3
69
suprachoroidal CLS-TA + suprachoroidal sham + IVT afliberceptPhase 3
69
4 mg CLS-TA + Sham + IVT afliberceptPhase 2
44